{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:30:38Z","timestamp":1792899038680,"version":"4.5.0"},"reference-count":36,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"unspecified","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"NIH\/NCI Cancer Center Support Grant","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"Bristol Myers Squibb"},{"name":"Celldex Therapeutics, Inc."}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,6,9]]},"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Phase 1\/2 dose-escalation and expansion study evaluating varlilumab, a fully human agonist anti-CD27 mAb, with nivolumab in anti-PD-1\/L1 na\u00efve, refractory solid tumors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Phase 1 evaluated the safety of varlilumab (0.1\u201310 mg\/kg) with nivolumab (3 mg\/kg) administered once every 2 weeks. Phase 2 evaluated varlilumab regimens (3 mg\/kg once every 2 weeks, 3 mg\/kg once every 12 weeks, and 0.3 mg\/kg once every 4 weeks) with nivolumab 240 mg once every 2 weeks in tumor-specific cohorts. Primary objective was safety; key clinical endpoints included objective response rate (ORR) and overall survival rate at 12 months (OS12) (glioblastoma (GBM) only). Exploratory objectives included determination of effects on peripheral blood and intratumoral immune signatures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>175 patients were enrolled (36 in phase 1 and 139 in phase 2). Phase 1 dose-escalation proceeded to the highest varlilumab dose level without determining a maximum tolerated dose. In phase 2, ORR were ovarian 12.5%, squamous cell carcinoma of the head and neck 12.5%, colorectal cancer 5%, and renal cell carcinoma 0%; GBM OS12 was 40.9%. Increased tumor PD-L1 and intratumoral T cell infiltration were observed in ovarian cancer patients, with increases of \u22655% associated with better progression-free survival. The most common treatment related adverse events were fatigue (18%), pruritus (16%), and rash (15%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Varlilumab and nivolumab were well tolerated, without significant toxicity beyond that expected for each agent alone. Clinical activity was observed in patients that are typically refractory to anti-PD-1 therapy, however, overall was not greater than expected for nivolumab monotherapy. Treatment was associated with proinflammatory changes in the tumor microenvironment, particularly in ovarian cancer where the changes were associated with better clinical outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02335918\">NCT02335918<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2022-005147","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T12:20:16Z","timestamp":1659961216000},"page":"e005147","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":69,"title":["Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct02335918","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0542-6054","authenticated-orcid":false,"given":"Rachel E","family":"Sanborn","sequence":"first","affiliation":[{"name":"Providence Cancer Institute, Earle A. Chiles Research Institute, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Pishvaian","sequence":"additional","affiliation":[{"name":"Department of Oncology, Georgetown-Lombardi Comprehensive Cancer Center, Washington, District of Columbia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret K","family":"Callahan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Weise","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Institute, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branimir I","family":"Sikic","sequence":"additional","affiliation":[{"name":"Clinical and Translational Research Unit, Stanford Cancer Institute, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Rahma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C","family":"Cho","sequence":"additional","affiliation":[{"name":"Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naiyer A","family":"Rizvi","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Columbia University Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Sznol","sequence":"additional","affiliation":[{"name":"Smilow Cancer Hospital, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9503-2130","authenticated-orcid":false,"given":"Jose","family":"Lutzky","sequence":"additional","affiliation":[{"name":"Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie E","family":"Bauman","sequence":"additional","affiliation":[{"name":"University of Arizona Cancer Center, Tuscon, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda L","family":"Bitting","sequence":"additional","affiliation":[{"name":"Wake Forest Baptist Health, Winston-Salem, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Starodub","sequence":"additional","affiliation":[{"name":"Parkview Research Center, Fort Wayne, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Jimeno","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Reardon","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kaley","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Department of Neurology, Columbia Presbyterian Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim M","family":"Baehring","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Yale New Haven Health Smilow Cancer Hospital, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa S","family":"Subramaniam","sequence":"additional","affiliation":[{"name":"Department of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanny B","family":"Aragon-Ching","sequence":"additional","affiliation":[{"name":"Inova Schar Cancer Institute, Fairfax, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R","family":"Hawthorne","sequence":"additional","affiliation":[{"name":"Celldex Therapeutics Inc New Haven, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Rawls","sequence":"additional","affiliation":[{"name":"Celldex Therapeutics Inc, Hampton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1164-7614","authenticated-orcid":false,"given":"Michael","family":"Yellin","sequence":"additional","affiliation":[{"name":"Celldex Therapeutics Inc, Hampton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor","family":"Keler","sequence":"additional","affiliation":[{"name":"R & D, Celldex Therapeutics Inc, Hampton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,8,8]]},"reference":[{"key":"2025100305554923000_10.8.e005147.1","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.4049\/jimmunol.151.5.2426","article-title":"Regulation of CD27 expression on subsets of mature T-lymphocytes","volume":"151","author":"Hintzen","year":"1993","journal-title":"J Immunol"},{"key":"2025100305554923000_10.8.e005147.2","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.4049\/jimmunol.153.12.5422","article-title":"CD27 is a signal-transducing molecule involved in CD45RA+ naive T cell costimulation","volume":"153","author":"Kobata","year":"1994","journal-title":"J Immunol"},{"key":"2025100305554923000_10.8.e005147.3","doi-asserted-by":"publisher","DOI":"10.1038\/80877"},{"key":"2025100305554923000_10.8.e005147.4","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030916"},{"key":"2025100305554923000_10.8.e005147.5","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.12.7432"},{"key":"2025100305554923000_10.8.e005147.6","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830251017"},{"key":"2025100305554923000_10.8.e005147.7","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.1996.d01-732.x"},{"key":"2025100305554923000_10.8.e005147.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.11.013"},{"key":"2025100305554923000_10.8.e005147.9","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20160784"},{"key":"2025100305554923000_10.8.e005147.10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3308"},{"key":"2025100305554923000_10.8.e005147.11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3057"},{"key":"2025100305554923000_10.8.e005147.12","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2016.70.1508","article-title":"Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors","volume":"35","author":"Burris","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025100305554923000_10.8.e005147.13","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1182\/bloodadvances.2019001079","article-title":"Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies","volume":"4","author":"Ansell","year":"2020","journal-title":"Blood Adv"},{"key":"2025100305554923000_10.8.e005147.14","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00262-017-1954-6","article-title":"PD-1 and PD-L1 antibodies in cancer: current status and future directions","volume":"66","author":"Balar","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"2025100305554923000_10.8.e005147.15","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0218-5"},{"key":"2025100305554923000_10.8.e005147.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025100305554923000_10.8.e005147.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00088-1"},{"key":"2025100305554923000_10.8.e005147.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.02.004"},{"key":"2025100305554923000_10.8.e005147.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694"},{"key":"2025100305554923000_10.8.e005147.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665"},{"key":"2025100305554923000_10.8.e005147.21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02059"},{"key":"2025100305554923000_10.8.e005147.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252"},{"key":"2025100305554923000_10.8.e005147.23","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025100305554923000_10.8.e005147.24","doi-asserted-by":"publisher","DOI":"10.1038\/ni869"},{"key":"2025100305554923000_10.8.e005147.25","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700384"},{"key":"2025100305554923000_10.8.e005147.26","first-page":"199","article-title":"Intratumoral expression of MIP-1beta induces antitumor responses in a pre-established tumor model through chemoattracting T cells and NK cells","volume":"1","author":"Luo","year":"2004","journal-title":"Cell Mol Immunol"},{"key":"2025100305554923000_10.8.e005147.27","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954"},{"key":"2025100305554923000_10.8.e005147.28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI87324"},{"key":"2025100305554923000_10.8.e005147.29","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1B results from the javelin solid tumor trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100305554923000_10.8.e005147.30","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz135"},{"key":"2025100305554923000_10.8.e005147.31","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"2025100305554923000_10.8.e005147.32","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.11.113","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"29","author":"Garcia-Diaz","year":"2019","journal-title":"Cell Rep"},{"key":"2025100305554923000_10.8.e005147.33","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","article-title":"Revisiting the role of CD4+ T cells in cancer immunotherapy-new insights into old paradigms","volume":"28","author":"Tay","year":"2021","journal-title":"Cancer Gene Ther"},{"key":"2025100305554923000_10.8.e005147.34","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1249561"},{"key":"2025100305554923000_10.8.e005147.35","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ccell.2017.11.001","article-title":"Antibody tumor targeting is enhanced by CD27 agonists through myeloid recruitment","volume":"32","author":"Turaj","year":"2017","journal-title":"Cancer Cell"},{"key":"2025100305554923000_10.8.e005147.36","doi-asserted-by":"crossref","unstructured":"Shapira-Frommer R , MGv D , Dobrenkov K . O83 phase 1 study of an anti-CD27 agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors. J ImmunoTher Cancer 2020;8.","DOI":"10.1136\/LBA2019.3"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-005147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:55:59Z","timestamp":1759496159000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-005147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,8]]},"published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1136\/jitc-2022-005147"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-005147","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8]]}}}